Tutt ANJ et al. [26] reported that one year of adjuvant olaparib following the completion of local treatment and neoadjuvant or adjuvant chemotherapy led to a significant improvement in invasive disease-free survival (DFS) and distant DFS of patients with HER2-negative early BC harboring BRCA1 or BRCA2 germline pathogenic variants, who had high-risk clinicopathological factors. The gene discussed is BRCA1; the disease is breast cancer.